SOLNA, Sweden, Feb. 3, 2023 /PRNewswire/ -- Hemcheck has received a follow-up order from its French distributor, Eurobio Scientific, corresponding to approximately SEK 80,000. The order concerns instruments for diagnostic use.
- We have a positive trend in terms of sales, which is very positive. Several of our distributors are very active and there is clear potential in especially the larger markets. We hope and believe we will get more similar orders, says Joen Averstad, CEO of Hemcheck.
For further information contact:
Hemcheck Sweden AB (publ)
Joen Averstad, CEO
Tel: +46 76 108 8191
Email: joen.averstad@hemcheck.com
About Hemcheck
Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection. The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately and is also a biomarker for acute medical conditions. Hemcheck's goal is to contribute to improved healthcare by offering user-friendly solutions for the detection of hemolysed blood samples in direct connection with blood sampling near the patient. By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs. The company is listed on the Nasdaq First North Growth Market.
FNCA Sweden AB, 08-528 00 399, info@fnca, is the Certified Adviser to the company.
The following files are available for download:
https://mb.cision.com/Main/16884/3708906/1825909.pdf | HC PM Eurobio 2023 ENG |
View original content:https://www.prnewswire.co.uk/news-releases/hemcheck-has-received-a-follow-up-order-from-its-french-distributor-301738478.html
